Literature DB >> 15163893

Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis.

Nathalie Saidenberg-Kermanac'h1, Natacha Bessis, Delphine Lemeiter, Marie-Christine de Vernejoul, Marie-Christophe Boissier, Martine Cohen-Solal.   

Abstract

To evaluate the respective action of IL-4, an anti-inflammatory cytokine, and OPG, an inhibitor of bone resorption, on the inflammatory process and the associated bone resorption in collagen-induced arthritis (CIA). After CIA induction, DBA/1 mice were treated with OPG or with IL-4 DBA/1 transfected fibroblasts or both OPG + IL-4. CIA significantly improved in IL-4 groups. OPG had no effect on arthritis clinical scores but histologic scores were reduced in OPG, IL-4, and OPG + IL-4 groups vs. nontreated CIA mice. OPG increased significantly BMD and decreased by 45% D-pyridinolin levels. Moreover association of IL-4 and OPG exerted an additive effect of BMD and resorption marker (-68%). Production of IFN-gamma in the supernatants of spleen cells was reduced in IL-4 treated mice. OPG had a moderate effect on IFN-gamma, but potentiated the inhibitory effect of IL-4. OPG and IL-4 prevent bone loss in CIA-mice model and could have additive effects on IFN-gamma secretion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163893     DOI: 10.1023/B:JOCI.0000029116.12371.bf

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  51 in total

1.  Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients.

Authors:  S Kotake; N Udagawa; M Hakoda; M Mogi; K Yano; E Tsuda; K Takahashi; T Furuya; S Ishiyama; K J Kim; S Saito; T Nishikawa; N Takahashi; A Togari; T Tomatsu; T Suda; N Kamatani
Journal:  Arthritis Rheum       Date:  2001-05

2.  Osteoclastogenesis in iliac bone marrow of patients with rheumatoid arthritis.

Authors:  Y Toritsuka; N Nakamura; S B Lee; J Hashimoto; N Yasui; K Shino; T Ochi
Journal:  J Rheumatol       Date:  1997-09       Impact factor: 4.666

3.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

4.  Osteoclasts are essential for TNF-alpha-mediated joint destruction.

Authors:  Kurt Redlich; Silvia Hayer; Romeo Ricci; Jean-Pierre David; Makiyeh Tohidast-Akrad; George Kollias; Günter Steiner; Josef S Smolen; Erwin F Wagner; Georg Schett
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

5.  IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis.

Authors:  J M Woods; K J Katschke; M V Volin; J H Ruth; D C Woodruff; M A Amin; M A Connors; H Kurata; K Arai; G K Haines; P Kumar; A E Koch
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

6.  Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis.

Authors:  B J Harrison; C E Hutchinson; J Adams; I N Bruce; A L Herrick
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

7.  A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3.

Authors:  S Morony; C Capparelli; R Lee; G Shimamoto; T Boone; D L Lacey; C R Dunstan
Journal:  J Bone Miner Res       Date:  1999-09       Impact factor: 6.741

8.  Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis.

Authors:  Giuseppe Campagnuolo; Brad Bolon; Ulrich Feige
Journal:  Arthritis Rheum       Date:  2002-07

9.  Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.

Authors:  Georg Schett; Kurt Redlich; Silvia Hayer; Jochen Zwerina; Brad Bolon; Colin Dunstan; Birgit Görtz; Andreas Schulz; Helga Bergmeister; Giorgos Kollias; Günter Steiner; Josef S Smolen
Journal:  Arthritis Rheum       Date:  2003-07

10.  Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast.

Authors:  T Akatsu; T Murakami; M Nishikawa; K Ono; N Shinomiya; E Tsuda; S Mochizuki; K Yamaguchi; M Kinosaki; K Higashio; M Yamamoto; K Motoyoshi; N Nagata
Journal:  Biochem Biophys Res Commun       Date:  1998-09-18       Impact factor: 3.575

View more
  13 in total

1.  Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: a novel mechanism mediating its blockade of osteoclastogenesis.

Authors:  Jing Cheng; Jianzhong Liu; Zhenqi Shi; Duorong Xu; Shaokai Luo; Gene P Siegal; Xu Feng; Shi Wei
Journal:  J Cell Biochem       Date:  2011-11       Impact factor: 4.429

Review 2.  Inflammatory and immune pathways in the pathogenesis of periodontal disease.

Authors:  Ali Cekici; Alpdogan Kantarci; Hatice Hasturk; Thomas E Van Dyke
Journal:  Periodontol 2000       Date:  2014-02       Impact factor: 7.589

Review 3.  The function of dendritic cells in modulating the host response.

Authors:  L Song; G Dong; L Guo; D T Graves
Journal:  Mol Oral Microbiol       Date:  2017-10-09       Impact factor: 3.563

4.  Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment.

Authors:  Aurore Miellot-Gafsou; Jérôme Biton; Elvire Bourgeois; André Herbelin; Marie-Christophe Boissier; Natacha Bessis
Journal:  Immunology       Date:  2010-01-27       Impact factor: 7.397

5.  A bivariate whole genome linkage study identified genomic regions influencing both BMD and bone structure.

Authors:  Xiao-Gang Liu; Yong-Jun Liu; Jianfeng Liu; Yufang Pei; Dong-Hai Xiong; Hui Shen; Hong-Yi Deng; Christopher J Papasian; Betty M Drees; James J Hamilton; Robert R Recker; Hong-Wen Deng
Journal:  J Bone Miner Res       Date:  2008-11       Impact factor: 6.741

Review 6.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

Review 7.  Host response mechanisms in periodontal diseases.

Authors:  Nora Silva; Loreto Abusleme; Denisse Bravo; Nicolás Dutzan; Jocelyn Garcia-Sesnich; Rolando Vernal; Marcela Hernández; Jorge Gamonal
Journal:  J Appl Oral Sci       Date:  2015 May-Jun       Impact factor: 2.698

8.  Simultaneous analysis of T helper subsets (Th1, Th2, Th9, Th17, Th22, Tfh, Tr1 and Tregs) markers expression in periapical lesions reveals multiple cytokine clusters accountable for lesions activity and inactivity status.

Authors:  Ana Claudia Araujo-Pires; Carolina Favaro Francisconi; Claudia Cristina Biguetti; Franco Cavalla; Andreza Maria Fabio Aranha; Ariadne Letra; Ana Paula Favaro Trombone; Marcelo Faveri; Renato Menezes Silva; Gustavo Pompermaier Garlet
Journal:  J Appl Oral Sci       Date:  2014 Jul-Aug       Impact factor: 2.698

9.  RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.

Authors:  Marina Stolina; Georg Schett; Denise Dwyer; Steven Vonderfecht; Scot Middleton; Diane Duryea; Efrain Pacheco; Gwyneth Van; Brad Bolon; Ulrich Feige; Debra Zack; Paul Kostenuik
Journal:  Arthritis Res Ther       Date:  2009-12-11       Impact factor: 5.156

Review 10.  Gene therapy for arthritis.

Authors:  Russell S Traister; Raphael Hirsch
Journal:  Mod Rheumatol       Date:  2008-01-05       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.